Traduction de «al transdermal » (Néerlandais → Français) :

FENTANYL SANDOZ 75 µG/H MATRIX TRANSDERMÁLNA NÁPLAST FENTANYL SANDOZ 100 µG/H MATRIX TRANSDERMÁLNA NÁPLAST FENTANILO MATRIX SANDOZ 12,5 µG/H PARCHES TRANSDÉRMICOS EFG FENTANILO MATRIX SANDOZ 25 µG/H PARCHES TRANSDÉRMICOS EFG FENTANILO MATRIX SANDOZ 50 µG/H PARCHES TRANSDÉRMICOS EFG FENTANILO MATRIX SANDOZ 75 µG/H PARCHES TRANSDÉRMICOS EFG FENTANILO MATRIX SANDOZ 100 µG/H PARCHES TRANSDÉRMICOS EFG MEZOLAR MATRIX 12 MICROGRAM/HOUR TRANSDERMAL PATCH MEZOLAR MATRIX 25 MICROGRAM/HOUR TRANSDERMAL PATCH MEZOLAR MATRIX 50 MICROGRAM/HOUR TRANSDERMAL PATCH MEZOLAR MATRIX 75 MICROGRAM/HOUR TRANSDERMAL PATCH MEZOLAR MATRIX 100 MICROGRAM/HOUR TRANSDERMAL PATCH
FENTANILO MATRIX SANDOZ 12,5 µG/H PARCHES TRANSDÉRMICOS EFG FENTANILO MATRIX SANDOZ 25 µG/H PARCHES TRANSDÉRMICOS EFG FENTANILO MATRIX SANDOZ 50 µG/H PARCHES TRANSDÉRMICOS EFG FENTANILO MATRIX SANDOZ 75 µG/H PARCHES TRANSDÉRMICOS EFG FENTANILO MATRIX SANDOZ 100 µG/H PARCHES TRANSDÉRMICOS EFG MEZOLAR MATRIX 12 MICROGRAM/HOUR TRANSDERMAL PATCH MEZOLAR MATRIX 25 MICROGRAM/HOUR TRANSDERMAL PATCH MEZOLAR MATRIX 50 MICROGRAM/HOUR TRANSDERMAL PATCH MEZOLAR MATRIX 75 MICROGRAM/HOUR TRANSDERMAL PATCH MEZOLAR MATRIX 100 MICROGRAM/HOUR TRANSDERMAL PATCH

L. Allan et al.: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
L. Allan et al. : Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.

(Cole 2007) Cole JA, Norman H, Doherty M, Walker AM. Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal
(Cole 2007) Cole JA, Norman H, Doherty M, Walker AM. Venous Thromboembolism, Myocardial Infarction, and Stroke Among

Exelon/Exelon Patch (USD 252 million, +9% cc) has continued to grow based on increasing demand for Exelon Patch, with the transdermal form of the medicine generating more than 67% of total Exelon sales in the second quarter compared to 52% in the same period in 2009.
Exelon/Exelon Patch (USD 252 millions, +9% tcc) a continué de croître sous l’effet d’une demande grandissante pour Exelon Patch. Cette forme transdermique du médicament a engendré au deuxième trimestre plus de 67% du chiffre d'affaires total d'Exelon par rapport à 52% au deuxième trimestre 2009.

Due to increasing demand for Exelon Patch, the transdermal form of the medicine generates now more than 70% of total Exelon sales in the third quarter compared to 56% in the same period in 2009.
En raison d’une demande grandissante pour Exelon Patch, la forme transdermique du médicament a engendré au troisième trimestre plus de 70% du chiffre d'affaires total d'Exelon, en comparaison de 56% dans la même période de 2009.

The Transdermal Contraceptive Patch: An Updated Review of the Literature. Clin Obstet
The Transdermal Contraceptive Patch: An Updated Review of the Literature.

Tassinari D, Drudi F, Rosati M et al. Transdermal opioids as front line treatment of moderate to severe cancer pain: a systematic review.
Tassinari D, Drudi F, Rosati M et al. The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review.

Elke pleister TRINIPATCH 15 bevat 67,2 mg nitroglycerine (67,2 mg pro system. transderm.
Chaque dispositif de TRINIPATCH 15 contient 67,2 mg de nitroglycerine (67,2 mg pro system. transderm.

Elke pleister TRINIPATCH 10 bevat 44,8 mg nitroglycerine (44,8 mg pro system. transderm.
Chaque dispositif de TRINIPATCH 10 contient 44,8 mg de nitroglycerine (44,8 mg pro system. transderm.

Elke pleister TRINIPATCH 5 bevat 22,4 mg nitroglycerine (22,4 mg pro system. transderm.
Chaque dispositif de TRINIPATCH 5 contient 22,4 mg de nitroglycerine (22,4 mg pro system. transderm.